Influenza vaccination should occur by the end of October, if possible.
A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.
The FDA has issued warning letters to several companies selling unapproved injectable products labeled as homeopathic.
The FDA has approved Elyxyb an oral solution formulation of celecoxib, for the acute treatment of migraine with or without aura in adults.
The Food and Drug Administration (FDA) has expanded the approval of Cymbalta to include treatment of fibromyalgia in pediatric patients 13 to 17 years of age.
To expedite development, the FDA has created a special emergency program called the Coronavirus Treatment Acceleration Program.
For patients suspected of having COVID-19, undergoing REMS-required testing to obtain a medication may put others at risk.
The FDA has approved Anjeso (meloxicam injection; Baudax Bio) for the management of moderate to severe pain, alone or in combination with NSAIDs in adult patients.
Diclofenac sodium topical gel and olopatadine HCl ophthalmic drops will soon be available over-the-counter (OTC) after the the Food and Drug Administration (FDA) switched the status of these products from prescription to nonprescription.
Strontium89 (Strontium Chloride Sr-89 injection), a radiopharmaceutical indicated for the relief of bone pain in patients with painful skeletal metastases, has been made available by Q BioMed.
